Revofil Aquashine BR Soft (2x2ml)

Aquashine BR Soft works by providing an immediate surge of hyaluronic acid-based hydration while simultaneously delivering bio-mimetic peptides. These peptides downregulate the melanocyte-stimulating hormone (MSH), which directly reduces pigment production. Unlike the Teoxane RHA technology, which prioritizes stretch and movement, Aquashine focuses on biochemical skin remodeling and brightening.

Injectable treatments are not recommended during the lactation period. There are no definitive studies on the transfer of specific peptide sequences into breast milk. It is advised to postpone elective skin revitalization until the breastfeeding period has concluded.

The formulation contains non-crosslinked Hyaluronic Acid (15 mg/ml) and a brightening peptide complex (Oligopeptide-34, Oligopeptide-72, Oligopeptide-24, Decapeptide-23) along with 14 vitamins and 24 amino acids for comprehensive dermal repair.

Standard treatment involves the administration of one 2 ml syringe per session, usually performed in a series of 3 sessions spaced 4 weeks apart. The gel is injected into the mid-to-deep dermis using micro-papular or linear threading techniques. Dosage may vary if the patient is also receiving targeted lip hydration or other localized aesthetic treatments.

Common side effects include minor redness, tiny papules at the injection site, and potential localized bruising. These typically resolve within 24 to 72 hours. To accelerate the healing of these micro-injection marks, patients should follow a strict aftercare protocol. If any unusual skin blanching occurs, immediately consult our safety guide.

Alcohol consumption should be avoided for 24 hours before and after the procedure. Alcohol is a known vasodilator that can increase the severity of post-injection swelling and worsen bruising at the multiple micro-injection points required for skin boosters.

This treatment is strictly contraindicated for pregnant women. Although hyaluronic acid is naturally occurring, there is no clinical data regarding the safety of bio-mimetic peptide complexes on fetal development. We maintain high safety standards and recommend waiting until after childbirth.